ROAM provides a methodology for assessing the “attractiveness for abuse” of a target drug versus a comparator, allowing you to:
- Estimate the relative attractiveness of not-yet-marketed or newly marketed formulations to a population’s “early adopters”
- Gauge the attractiveness of a marketed drug
- Track changes in attractiveness over time